Riudavets, M, Auclin, E, Mosteiro, M, Dempsey, N, Majem, M, Prelaj, A, López-Castro, R, Bosch-Barrera, J, Pilotto, S, Escalera, E, Tagliamento, M, Mosquera, J, Zalcman, G, Nana, FA, Ponce, S, Albarrán-Artahona, V, Dal Maso, A, Spotti, M, Mielgo, X, Mussat, E, Reyes, R, Benítez, JC, Lupinacci, L, Duchemann, B, De Giglio, A, Blaquier, JB, Audigier-Valette, C, Scheffler, M, Nadal, E, Lopes, G, Signorelli, D, Garcia-Campelo, R, Menis, J, Bluthgen, V, Campayo, M, Recondo, G, Besse, B, Mezquita, L, Planchard, D. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2024; 25(3)DOI:10.1016/j.cllc.2023.11.007. PMID:38105153. IF:3.300(Q2/4D).

Torres-Esquius, S, Llop-Guevara, A, Gutiérrez-Enríquez, S, Romey, M, Teulé, A, Llort, G, Herrero, A, Sánchez-Henarejos, P, Vallmajó, A, González-Santiago, S, Chirivella, I, Cano, JM, Graña, B, Simonetti, S, de Corcuera, ID, Cajal, TRY, Sanz, J, Serrano, S, Otero, A, Churruca, C, Sánchez-Heras, AB, Servitja, S, Guillén-Ponce, C, Brunet, J, Denkert, C, Serra, V, Balmaña, J. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Network Open. 2024; 7(4)DOI:10.1001/jamanetworkopen.2024.7811. PMID:38648056. IF:9.700(Q1/1D).

Lubinski, J, Kotsopoulos, J, Moller, P, Pal, T, Eisen, A, Peck, L, Karlan, BY, Aeilts, A, Eng, C, Bordeleau, L, Foulkes, WD, Tung, N, Couch, FJ, Fruscio, R, Cajal, T, Singer, CF, Neuhausen, SL, Zakalik, D, Cybulski, C, Gronwald, J, Huzarski, T, Stempa, K, Dungan, J, Cullinane, C, Olopade, OI, Metcalfe, K, Sun, P, Narod, SA. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 2024; DOI:10.1001/jamaoncol.2023.6944. PMID:38421676. IF:20.100(Q1/1D).

Motzer, RJ, Porta, C, Eto, M, Powles, T, Gruenwald, V, Hutson, TE, Alekseev, B, Rha, SY, Merchan, J, Goh, JC, Lalani, AKA, De Giorgi, U, Melichar, B, Hong, SH, Gurney, H, Mendez-Vidal, MJ, Kopyltsov, E, Tjulandin, S, Gordoa, TA, Kozlov, V, Alyasova, A, Winquist, E, Maroto, P, Kim, M, Peer, A, Procopio, G, Takagi, T, Wong, SR, Bedke, J, Schmidinger, M, Rodriguez-Lopez, K, Burgents, J, He, CX, Okpara, CE, Mckenzie, J, Choueiri, TK. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(11)DOI:10.1200/JCO.23.01569. PMID:38227898. IF:41.900(Q1/1D).

Rofes, P, Dueñas, N, del Valle, J, Navarro, M, Balmaña, J, Ramón y Cajal, T, Tuset, N, Castillo, C, González, S, Brunet, J, Capellá, G, Lázaro, C, Pineda, M. Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation. Cancer Medicine. 2024; 13(7)DOI:10.1002/cam4.7041. PMID:38558366. IF:3.100(Q2/5D).

Rueda, AG, Taus, A, Alvarez, RA, Bernabé-Caro, R, Chara, L, López-Brea, M, Vilà, L, González, MAS, Aldagalán, ADD, Herrera, BE, Castro, RL, Cabellos, RA, Doménech, M, Falagan, S, Vega, AM, Aguado, C, Barba, A, Ureña, MTD, Isla, D, Hernández, LB, Pérez, JLF, Juan-Vidal, O, Massuti, B, Mielgo-Rubio, X, Ortega, AL, Catot, S, Dómine, M, Escoín-Pérez, C, Navalón, FG, Gil-Bazo, I, Muñoz, S, Rodríguez-Abreu, D, Roldán, RMV, Curbera, GA, León-Mateos, L, Padilla, A, Lario, AP, Sánchez-Torres, JM, Garrido, P. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical & Translational Oncology. 2024; 26(9)DOI:10.1007/s12094-024-03404-9. PMID:38512450. IF:2.500(Q3/6D).